We are live on
!
Find out more
Point72 Asset Management Portfolio holdings
AUM
$78.1B
1-Year Est. Return
55.25%
This Fund
S&P 500
This Quarter
Est. Return
-2.81%
1 Year Est. Return
+55.25%
3 Year Est. Return
+151.79%
5 Year Est. Return
+188.05%
10 Year Est. Return
+800.63%
AUM
$25.2B
AUM Growth
+$145M
(+0.58%)
Cap. Flow
+$1.25B
Cap. Flow
% of AUM
4.95%
Top 10 Holdings %
Top 10 Hldgs %
11.42%
Holding
1,496
New
423
Increased
299
Reduced
316
Closed
358
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$278M |
| 2 |
Analog Devices
ADI
|
+$181M |
| 3 |
Target
TGT
|
+$172M |
| 4 |
Visa
V
|
+$150M |
| 5 |
Broadcom
AVGO
|
+$148M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$454M |
| 2 |
Micron Technology
MU
|
+$168M |
| 3 |
Suncor Energy
SU
|
+$146M |
| 4 |
Cheniere Energy
LNG
|
+$129M |
| 5 |
Amazon
AMZN
|
+$124M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.22% |
| 2 | Technology | 16.94% |
| 3 | Consumer Discretionary | 10.54% |
| 4 | Industrials | 7.2% |
| 5 | Energy | 6.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
851
TriSalus Life Sciences
TLSI
$284M
| $1.96M | 0.01% |
200,000
| – | – |
|
|
JNCE
852
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $1.93M | 0.01% |
284,831
+30,900
| +12% | +$220K |
|
|
RXDX
853
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $1.89M | 0.01% |
50,000
-84,537
| -63% | -$3.34M |
|
|
CNVY
854
DELISTED
Convey Health Solutions Holdings, Inc.
CNVY
| $1.88M | 0.01% |
287,000
-144,611
| -34% | -$954K |
|
855
PureCycle Technologies
PCT
$1.38B
| $1.85M | 0.01% |
231,700
-184,800
| -44% | -$1.35M |
|
856
CareDx
CDNA
$2.35B
| $1.85M | 0.01% |
50,083
-168,893
| -77% | -$6.58M |
|
|
CMBT
857
CMB.TECH NV
CMBT
$4.62B
| $1.85M | 0.01% |
+175,100
| New | +$1.74M |
|
|
SHCR
858
DELISTED
Sharecare, Inc. Class A Common Stock
SHCR
| $1.84M | 0.01% |
745,661
| – | – |
|
|
ARVL
859
DELISTED
Arrival Ordinary Shares
ARVL
| $1.82M | 0.01% |
+9,738
| New | +$2.1M |
|
860
International Seaways
INSW
$4.49B
| $1.81M | 0.01% |
+100,500
| New | +$1.63M |
|
861
Personalis
PSNL
$1.44B
| $1.81M | 0.01% |
221,412
+19,699
| +10% | +$204K |
|
862
Ares Management
ARES
$31.5B
| $1.73M | 0.01% |
21,300
-13,500
| -39% | -$1.04M |
|
863
Pulmonx
LUNG
$83.6M
| $1.72M | 0.01% |
69,400
-248,507
| -78% | -$6.42M |
|
864
Aligos Therapeutics
ALGS
$29.3M
| $1.72M | 0.01% |
32,000
+27,580
| +624% | +$2.21M |
|
865
Neuropace
NPCE
$467M
| $1.72M | 0.01% |
209,176
+72,976
| +54% | +$630K |
|
866
Cipher Digital
CIFR
$7.65B
| $1.71M | 0.01% |
470,600
+1,400
| +0.3% | +$4.49K |
|
867
BioXcel Therapeutics
BTAI
$26M
| $1.69M | 0.01% |
+5,056
| New | +$1.47M |
|
868
Bio-Techne
TECH
$11.2B
| $1.69M | 0.01% |
+15,572
| New | +$1.61M |
|
|
POSH
869
DELISTED
Poshmark, Inc. Class A Common Stock
POSH
| $1.69M | 0.01% |
133,153
-260,647
| -66% | -$3.77M |
|
|
EXAS
870
DELISTED
Exact Sciences
EXAS
| $1.69M | 0.01% |
+24,100
| New | +$1.76M |
|
|
AZUL
871
DELISTED
Azul
AZUL
| $1.68M | 0.01% |
111,400
+13,000
| +13% | +$186K |
|
872
Check Point Software Technologies
CHKP
$12.8B
| $1.67M | 0.01% |
+12,100
| New | +$1.58M |
|
873
PUT
Wayfair
W
$14.2B
| $1.66M | 0.01% |
+15,000
| New | +$2.11M |
|
874
Aurora
AUR
$13.1B
| $1.65M | 0.01% |
294,562
+285,000
| +2,981% | +$1.64M |
|
875
PUT
RH
RH
$3.7B
| $1.63M | 0.01% |
+5,000
| New | +$2M |
|
Similar funds
CBU
BC
Point72 Asset Management's Q1 2022 Portfolio in Review
As of Q1 2022, Point72 Asset Management held 1,496 positions worth $25.2B, up 0.58% from $25B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Point72 Asset Management deployed $1.25B of net new capital in Q1 2022, opening 423 new positions and adding to 299 existing holdings. Its largest new stake was Target: 794,997 shares worth $169M.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 23% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Micron Technology, an estimated $168M trimmed.
- Point72 Asset Management's largest Q1 2022 buy was Target: 794,997 shares worth $169M.
- Point72 Asset Management added most to Merck in Q1 2022, an estimated $278M increase.
- Point72 Asset Management's biggest Q1 2022 reduction was Micron Technology, cutting an estimated $168M.
- Point72 Asset Management fully exited iShares Core S&P 500 ETF in Q1 2022, selling an estimated $454M.
- Point72 Asset Management's ten largest holdings make up 11% of its $25.2B portfolio in Q1 2022.
- Point72 Asset Management opened 423 new positions and closed 358 in Q1 2022.
- Point72 Asset Management's portfolio value rose 0.58% quarter-over-quarter to $25.2B.
Based on Point72 Asset Management's 13F filing for Q1 2022, filed 16 May 2022.